Organon & Co. Common (OGN) closed at $13.85 on November 3, 2026, up 0.2% from the previous close, on volume of 3,220,469 shares (30-day average 2,055,211).
Data as of November 3, 2026.
Organon Highlights Non-GAAP Metrics Amid Pending Merger
TipRanks (Fri, 30-Oct 8:46 AM ET)
Organon declares $0.02 dividend
Seeking Alpha News (Fri, 30-Oct 8:26 AM ET)
Organon Announces Quarterly Dividend
Business Wire (Fri, 30-Oct 8:25 AM ET)
Globe Newswire (Tue, 27-Oct 8:00 AM ET)
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
Business Wire (Mon, 19-Oct 7:30 AM ET)
Business Wire (Fri, 16-Oct 7:30 AM ET)
Business Wire (Thu, 1-Oct 8:00 AM ET)
PRNewswire (Mon, 28-Sep 8:02 AM ET)
Business Wire (Mon, 14-Sep 7:30 AM ET)
National Can-RISE Study to Help Close Critical Gaps in Menopause Research
Globe Newswire (Thu, 27-Aug 9:00 AM ET)
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Organon & Co. Common trades on the NYSE stock market under the symbol OGN.
As of November 3, 2026, OGN stock price climbed to $13.85 with 3,220,469 million shares trading.
OGN has a beta of 1.93, meaning it tends to be more sensitive to market movements. OGN has a correlation of 0.14 to the broad based SPY ETF.
OGN has a market cap of $3.64 billion. This is considered a Mid Cap stock.
Last quarter Organon & Co. Common reported $2 billion in Revenue and $.94 earnings per share. This met revenue expectation and missed earnings estimates by -$.01.
In the last 3 years, OGN traded as high as $23.10 and as low as $5.69.
The top ETF exchange traded funds that OGN belongs to (by Net Assets): IJR, VTI, VB, VBR, VXF.
OGN has outperformed the market in the last year with a price return of +106.4% while the SPY ETF gained +11.7%. OGN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +2.4% and +0.7%, respectively, while the SPY returned +1.2% and -1.6%, respectively.
OGN support price is $13.79 and resistance is $13.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OGN shares will trade within this expected range on the day.
